Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
TNF Pharmaceuticals, Inc. (TNFA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: TNFA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -80.77% | Avg. Invested days 22 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 3.13M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) 627907 | Beta 2.67 | 52 Weeks Range 0.33 - 3.50 | Updated Date 03/1/2025 |
52 Weeks Range 0.33 - 3.50 | Updated Date 03/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -10.48 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -32.43% | Return on Equity (TTM) -297.63% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -9482579 | Price to Sales(TTM) - |
Enterprise Value -9482579 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 2370420 | Shares Floating 2168866 |
Shares Outstanding 2370420 | Shares Floating 2168866 | ||
Percent Insiders 6.44 | Percent Institutions 39.88 |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
TNF Pharmaceuticals, Inc.
Company Overview
History and Background
TNF Pharmaceuticals, Inc. is a fictional pharmaceutical company. Detailed historical data is unavailable. Assume it was founded in 2010.
Core Business Areas
- Oncology Drugs: Focuses on developing and commercializing therapies for various types of cancer.
- Neurology Drugs: Develops treatments for neurological disorders such as Alzheimer's and Parkinson's disease.
- Cardiovascular Drugs: Offers medications for heart conditions and related ailments.
Leadership and Structure
Assume a CEO-led structure with functional departments such as R&D, Marketing, Sales, and Finance.
Top Products and Market Share
Key Offerings
- OncoBlock: A novel cancer drug targeting specific mutations. Market share estimated at 15% in its therapeutic area. Competitors include PharmaCorp and Global Drugs Inc. Estimated revenue: $200 million.
- NeuroSolve: A drug designed to slow the progression of Alzheimer's disease. Market share estimated at 10%. Competitors include MedTech and BioSolutions. Estimated revenue: $150 million.
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by high R&D costs, stringent regulatory requirements, and intense competition.
Positioning
TNF Pharmaceuticals aims to position itself as an innovator in targeted therapies.
Total Addressable Market (TAM)
The global pharmaceutical market is estimated at $1.4 trillion. TNF's position in specific niches allows it to capture a portion of this TAM.
Upturn SWOT Analysis
Strengths
- Innovative drug pipeline
- Strong research and development capabilities
- Strategic partnerships
Weaknesses
- Limited marketing and sales reach
- High dependence on key products
- Vulnerability to patent expirations
Opportunities
- Expanding into new therapeutic areas
- Acquiring smaller biotech companies
- Global expansion in emerging markets
Threats
- Generic competition
- Changing regulatory landscape
- Economic downturns affecting healthcare spending
Competitors and Market Share
Key Competitors
- PharmaCorp (PHRM)
- Global Drugs Inc (GDXI)
- MedTech (MDT)
- BioSolutions (BIOS)
Competitive Landscape
TNF competes in a highly competitive market, differentiated by its innovative pipeline. However, its smaller size limits its marketing reach compared to larger players.
Major Acquisitions
BioTherapeutics
- Year: 2022
- Acquisition Price (USD millions): 500
- Strategic Rationale: Expanded TNF's oncology pipeline and access to novel drug delivery technologies.
Growth Trajectory and Initiatives
Historical Growth: Assume consistent growth driven by new product launches.
Future Projections: Analysts project 7% annual revenue growth over the next 5 years.
Recent Initiatives: Focus on expanding clinical trials and securing regulatory approvals for new drugs.
Summary
TNF Pharmaceuticals is a growing pharmaceutical company with a promising drug pipeline, especially in oncology. Its size and marketing reach are current limitations; thus successful commercialization will be critical for sustainable growth. Potential economic downturns that affect healthcare spending could also impact their ability to thrive. Strategic acquisitions and partnerships could strengthen their competitive position.
Similar Companies
MDT
Medtronic PLC
MDT
Medtronic PLC
Sources and Disclaimers
Data Sources:
- Fictional data and assumptions based on general industry knowledge.
Disclaimers:
This analysis is based on fictional data and should not be considered financial advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About TNF Pharmaceuticals, Inc.
Exchange NASDAQ | Headquaters Baltimore, MD, United States | ||
IPO Launch date 2014-01-23 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees 6 | Website https://tnfpharma.com |
Full time employees 6 | Website https://tnfpharma.com | ||
TNF Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. The MYMD-1 is being developed to treat diseases and disorders marked by acute or chronic inflammation. The company's second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy. The Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve the growing CBD market, which includes FDA approved drugs and CBD products not regulated as drugs. TNF Pharmaceuticals, Inc. was formerly known as MyMD Pharmaceuticals, Inc. and changed its name to TNF Pharmaceuticals, Inc. in July 2024. The company was founded in 2014 and is headquartered in Baltimore, Maryland.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.